Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Dyne Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- HARMONIA TRIAL WILL ASSESS MULTI-SYSTEM EFFICACY, SAFETY AND TOLERABILITY OF Z-BASIVARSEN IN DM1 - - 48-WEEK TRIAL WILL ENROLL APPROXIMATELY 150 INDIVIDUALS, AND FIRST SITES ARE NOW OPEN FOR ENROLLMENT - - PRIMARY ENDPOINT IS THE FIVE TIMES SIT TO STAND (5XSTS) TEST; SECONDARY AND EXPLORATORY ENDPOINTS WILL ASSESS MUSCLE FUNCTION, CNS MANIFESTATIONS, AND PATIENT- AND CLINICIAN-REPORTED OUTCOMES - - HARMONIA TRIAL DESIGN AND PROTOCOL ALIGNED WITH FDA; TRIAL INTENDED TO SERVE AS CONFIRMATORY TRIAL FOR TRADITIONAL APPROVAL IN THE U.S. AND SUPPORT EX-U.S. MARKETING APPLICATIONS - WALTHAM, MASS., MARCH 08, 2026 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS, INC. (NASDAQ: DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED THE INITIATION OF THE PHASE 3 HARMONIA TRIAL OF ZELECIMENT BASIVARSEN (Z-BASIVARSEN, ALSO KNOWN AS DYNE-101), IN INDIVIDUALS WITH MYOTONIC DYSTROPHY TYPE 1 (DM1).

DYNE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 3 HARMONIA TRIAL OF Z-BASIVARSEN IN MYOTONIC DYSTROPHY TYPE 1 (DM1)

- NEW ANALYSES OUT TO 24-MONTHS SHOWED IMPROVEMENT IN HEART AND LUNG FUNCTION COMPARED TO EXPECTED DECLINES IN DMD NATURAL HISTORY - - DATA EXPAND ON PREVIOUSLY REPORTED RESULTS DEMONSTRATING THAT Z-ROSTUDIRSEN TREATMENT LED TO SUSTAINED FUNCTIONAL IMPROVEMENT ACROSS MULTIPLE CLINICAL MEASURES - WALTHAM, MASS., MARCH 08, 2026 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS, INC. (NASDAQ: DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED ADDITIONAL POSITIVE DATA FROM THE ONGOING PHASE 1/2 DELIVER CLINICAL TRIAL OF ZELECIMENT ROSTUDIRSEN (Z-ROSTUDIRSEN, ALSO KNOWN AS DYNE-251), IN INDIVIDUALS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO EXON 51 SKIPPING.

DYNE THERAPEUTICS ANNOUNCES NEW POSITIVE CARDIOPULMONARY RESULTS FROM DELIVER TRIAL OF Z-ROSTUDIRSEN IN DUCHENNE MUSCULAR DYSTROPHY (DMD)

- PLANNED SUBMISSION FOR U.S. ACCELERATED APPROVAL OF Z-ROSTUDIRSEN ON TRACK FOR Q2 2026; POTENTIAL LAUNCH IN Q1 2027 -

DYNE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

WALTHAM, MASS., FEB. 25, 2026 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS, INC . (NASDAQ: DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED THAT MANAGEMENT IS SCHEDULED TO PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

DYNE THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

- LATE-BREAKING POSTER TO FEATURE NEW POSITIVE CARDIOPULMONARY FUNCTION RESULTS FROM THE DELIVER TRIAL OF Z-ROSTUDIRSEN IN DMD -

DYNE THERAPEUTICS ANNOUNCES UPCOMING PRESENTATIONS ACROSS NEUROMUSCULAR PIPELINE AT 2026 MDA CLINICAL & SCIENTIFIC CONFERENCE

BOSTON, FEB. 02, 2026 (GLOBE NEWSWIRE) -- SPARROW PHARMACEUTICALS, A TARGETED CARDIOMETABOLIC THERAPEUTICS COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF CARLO INCERTI, M.D., TO ITS BOARD OF DIRECTORS, EFFECTIVE JANUARY 1, 2026. DR. INCERTI IS A HIGHLY ACCOMPLISHED EXECUTIVE WITH A STRONG BACKGROUND IN MEDICINE AND OVER 35 YEARS OF STRATEGIC EXPERIENCE IN THE BIOPHARMACEUTICAL INDUSTRY.

SPARROW APPOINTS BIOPHARMACEUTICAL INDUSTRY VETERAN, CARLO INCERTI, M.D. TO ITS BOARD OF DIRECTORS

- ZELECIMENT BASIVARSEN (Z-BASIVARSEN) DEMONSTRATED SUSTAINED FUNCTIONAL IMPROVEMENT ACROSS MULTIPLE CLINICAL MEASURES IN THE ONGOING ACHIEVE CLINICAL TRIAL - - EXPECT TO COMPLETE ENROLLMENT IN ACHIEVE REGISTRATIONAL EXPANSION COHORT IN EARLY Q2 2026 - WALTHAM, MASS., JAN. 20, 2026 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS, INC. (NASDAQ: DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED THAT THE MINISTRY OF HEALTH, LABOUR AND WELFARE (MHLW) IN JAPAN HAS GRANTED ORPHAN DRUG DESIGNATION FOR ZELECIMENT BASIVARSEN (Z-BASIVARSEN), FOR THE TREATMENT OF MYOTONIC MUSCULAR DYSTROPHY TYPE 1 (DM1).

DYNE THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN JAPAN FOR ZELECIMENT BASIVARSEN (DYNE-101) FOR MYOTONIC DYSTROPHY TYPE 1

WALTHAM, MASS., JAN. 07, 2026 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS, INC . (NASDAQ: DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED THAT JOHN COX, PRESIDENT AND CHIEF EXECUTIVE OFFICER, IS SCHEDULED TO PRESENT AT THE 44THANNUAL J.P. MORGAN HEALTHCARE CONFERENCE IN SAN FRANCISCO ON WEDNESDAY, JANUARY 14, 2026 AT 5:15 P.M. PT (8:15 P.M. ET).

DYNE THERAPEUTICS TO PRESENT AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

WALTHAM, MASS., DEC. 23, 2025 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS, INC . (NASDAQ: DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF VIKRAM KARNANI TO ITS BOARD OF DIRECTORS. MR. KARNANI BRINGS EXTENSIVE COMMERCIAL AND EXECUTIVE LEADERSHIP EXPERIENCE IN RARE DISEASE AND BIOPHARMACEUTICALS, SERVING AS THE CURRENT CHIEF EXECUTIVE OFFICER OF COLLEGIUM PHARMACEUTICAL AND HAVING SPENT NEARLY A DECADE LEADING SEVERAL LINES OF BUSINESS AND FUNCTIONS AT HORIZON THERAPEUTICS.

DYNE THERAPEUTICS APPOINTS VIKRAM KARNANI TO BOARD OF DIRECTORS

WALTHAM, MASS., DEC. 11, 2025 (GLOBE NEWSWIRE) -- DYNE THERAPEUTICS, INC. (NASDAQ: DYN), A CLINICAL-STAGE COMPANY FOCUSED ON DELIVERING FUNCTIONAL IMPROVEMENT FOR PEOPLE LIVING WITH GENETICALLY DRIVEN NEUROMUSCULAR DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UPSIZED UNDERWRITTEN PUBLIC OFFERING OF 21,827,549 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $18.44 PER SHARE, WHICH INCLUDES 2,847,071 SHARES ISSUED UPON THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK IN THE OFFERING. THE GROSS PROCEEDS TO DYNE FROM THE OFFERING WERE APPROXIMATELY $402.5 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY DYNE. ALL OF THE SHARES IN THE OFFERING WERE SOLD BY DYNE.

DYNE THERAPEUTICS ANNOUNCES CLOSING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK AND FULL EXERCISE BY UNDERWRITERS OF OPTION TO PURCHASE ADDITIONAL SHARES

Dyne Therapeutics, Inc.

DYN

Price

Financial Reports

No items found.

Press Releases

Dyne Therapeutics, Inc.

DYN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

DYN